Lotiglipron|CAS 2401892-75-7|DC Chemicals

Cas No.:	2401892-75-7
Chemical Name:	Lotiglipron
Synonyms:	lotiglipron [INN];2-({4-[(S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[1,3]dioxol-4-yl]piperidin-1-yl}methyl)-1-{[(S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid;Lotiglipron;US10676465, Example 10;1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]-;CS-0865718;BDBM450633;HY-153865;YI10W1K93A;2401892-75-7;SCHEMBL22009794;EX-A7734;PF-07081532;LOTIGLIPRON [USAN]
SMILES:	ClC1=CN=C(C=C1)[C@@]1(C)OC2=CC=CC(=C2O1)C1CCN(CC2=NC3C=CC(C(=O)O)=CC=3N2C[C@@H]2CCO2)CC1
Formula:	C₃₁H₃₁ClN₄O₅
M.Wt:	575.054646730423
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC74600	Lotiglipron	Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. It reduces glucose and body weight, and has the potential to be used in Type 2 diabetes mellitus (T2DM) research.
DC70577	LY3502970 (Orforglipron)	LY-3502970 (Orforglipron) is a potent, selective, orally active non-peptide agonist of glucagon-like peptide-1 (GLP-1) receptor.LY3502970 is a partial agonist, biased toward G protein activation over β-arrestin recruitment at the GLP-1R.
DC46189	Teduglutide	Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. Teduglutide prolongs the intestinotrophic properties of GLP-2 in animal models.
DC45570	Tirzepatide sodium salt (LY3298176)	Tirzepatide (LY3298176, GIP/GLP-1 RA, TZP) is a dual GIP/GLP-1 receptor agonist. Tirzepatide differentially induces internalization of the GIP and GLP-1 receptors with EC50 values of 18.2 nM and 18.1 nM, respectively.
DC45527	Avexitide	Avexitide (Exendin (9-39)) is a specific and competitive antagonist of glucagon-like peptide-1 (GLP-1) receptor.
DC10278	LGD-6972	LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.